Maximilian Hastreiter

Maximilian Hastreiter

Auto-generated profile, based on publicly available information

Maximilian Hastreiter

Dr von Hauner Children’s Hospital, University Hospital, and

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2014 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
TGTatyana Goldberg
Tatyana Goldberg
MHMaximilian Hecht
Maximilian Hecht
THTobias Hamp
Tobias Hamp
TKTimothy Karl
Timothy Karl
GYGuy Yachdav
Guy Yachdav
BRBurkhard Rost
Burkhard Rost
The prediction of protein sub-cellular localization is an important step toward elucidating protein function. For each query protein sequence, LocTree2 applies machine learning (profile kernel SVM) to predict the native sub-cellular localization in 18 classes for eukaryotes, in six for bacteria and in three for archaea. The method outputs a score that reflects the reliability of each prediction. LocTree2 has performed on par with or better than any other state-of-the-art method. Here, we report the availability of LocTree3 as a public web server. The server includes the machine learning-based LocTree2 and improves over it through the addition of homology-based inference. Assessed on sequence-unique data, LocTree3 reached an 18-state accuracy Q18 = 80 ± 3% for eukaryotes and a six-state accuracy Q6 = 89 ± 4% for bacteria. The server accepts submissions ranging from single protein sequences to entire proteomes. Response time of the unloaded server is about 90 s for a 300-residue eukaryotic protein and a few hours for an entire eukaryotic proteome not considering the generation of the alignments. For over 1000 entirely sequenced organisms, the predictions are directly available as downloads. The web server is available at http://www.rostlab.org/services/loctree3.

3 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MAManuel Albanese
Manuel Albanese
TTTakanobu Tagawa
Takanobu Tagawa
MBMickaël Bouvet
Mickaël Bouvet
LMLiridona Maliqi
Liridona Maliqi
Dominik LutterDominik Lutter
Dominik Lutter
WHWolfgang Hammerschmidt
Wolfgang Hammerschmidt
Significance: Most humans are infected for their lifetime with Epstein–Barr virus (EBV), which can cause cancer and other EBV-associated diseases. Infected individuals develop strong immune responses to this virus, in particular cytotoxic CD8 + T cells, but viral infection is never cleared nor is EBV eliminated from the body. This suggests that certain viral molecules might prevent effective elimination of EBV-infected cells by CD8 + T cells. EBV is rich in genes coding for microRNAs, many with unknown function. We show that viral microRNAs interfere with recognition and killing of EBV-infected cells by CD8 + T cells. Multiple mechanisms and molecules are targeted by microRNAs to achieve this immune evasion. Therefore, targeting of viral microRNAs may improve antiviral immunity and therapy.

12 September 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TTTakanobu Tagawa
Takanobu Tagawa
MAManuel Albanese
Manuel Albanese
MBMickaël Bouvet
Mickaël Bouvet
AMAndreas Moosmann
Andreas Moosmann
JMJosef Mautner
Josef Mautner
WHWolfgang Hammerschmidt
Wolfgang Hammerschmidt
Epstein-Barr virus (EBV) is a tumor virus that establishes lifelong infection in most of humanity, despite eliciting strong and stable virus-specific immune responses. EBV encodes at least 44 miRNAs, most of them with unknown function. Here, we show that multiple EBV miRNAs modulate immune recognition of recently infected primary B cells, EBV's natural target cells. EBV miRNAs collectively and specifically suppress release of proinflammatory cytokines such as IL-12, repress differentiation of naive CD4+ T cells to Th1 cells, interfere with peptide processing and presentation on HLA class II, and thus reduce activation of cytotoxic EBV-specific CD4+ effector T cells and killing of infected B cells. Our findings identify a previously unknown viral strategy of immune evasion. By rapidly expressing multiple miRNAs, which are themselves nonimmunogenic, EBV counteracts recognition by CD4+ T cells and establishes a program of reduced immunogenicity in recently infected B cells, allowing the virus to express viral proteins required for establishment of life-long infection.

25 February 2021 in Blood
Verified
Journal Article
Closed access
PDF file
SWSemjon Willier
Semjon Willier
PRPaula Rothämel
Paula Rothämel
MHMaximilian Hastreiter
Maximilian Hastreiter
JWJonas Wilhelm
Jonas Wilhelm
DSDana Stenger
Dana Stenger
TFTobias Feuchtinger
Tobias Feuchtinger
Emerging immunotherapies such as chimeric antigen receptor T cells have advanced the treatment of acute lymphoblastic leukemia. In contrast, long-term control of acute myeloid leukemia (AML) cannot be achieved by single lineage-specific targeting while sparing benign hematopoiesis. In addition, heterogeneity of AML warrants combinatorial targeting and several suitable immunotargets (HAVCR2/CD33 or HAVCR2/CLEC12A) were identified in adult AML. However, clinical and biologic characteristics differ between children and the elderly. Here, we analyzed 36 bone marrow (BM) samples of pediatric AML patients and 13 age-matched healthy donors using whole RNA-sequencing of sorted CD45dim and CD34+CD38-CD45dim BM populations and flow cytometry for surface expression of putative target antigens. Pediatric AML clusters apart from healthy myeloid BM precursors in principle component analysis. Immunotargets known from adult AML such as IL3RA were not overexpressed in pediatric AML compared to healthy precursors by RNA-sequencing. CD33 and CLEC12A were the most upregulated immunotargets on RNA level and showed the highest surface expression on AML detected by flow cytometry. KMT2A mutated infant AML cluster separately by RNA-sequencing, overexpress FLT3 and hence CD33/FLT3 co-targeting is an additional specific option for this subgroup. CLEC12A and CD33/CLEC12Adouble-positive expression was absent in CD34+CD38-CD45RA-CD90+ hematopoietic stem cells (HSC) and both are restricted to healthy hematopoietic tissue, while CD33 and FLT3 is expressed on HSC. In summary, we show that expression of immunotargets in pediatric AML differs from known expression profiles in adult AML. We identify CLEC12A/CD33 as preferential generic combinatorial immunotargets in pediatric AML and CD33/FLT3 as immunotargets specific for KMT2A mutated infant AML.

17 February 2021 in Clinical Genetics
Verified
Journal Article
Open access
PDF file
LSLuise A. Schuch
Luise A. Schuch
MFMaria Forstner
Maria Forstner
CRChristina Katharina Rapp
Christina Katharina Rapp
YLYang Li
Yang Li
DSDesiree E. C. Smith
Desiree E. C. Smith
MGMatthias Griese
Matthias Griese
Aminoacyl‐tRNA synthetases (ARSs) catalyze the first step of protein biosynthesis (canonical function) and have additional (non‐canonical) functions outside of translation. Bi‐allelic pathogenic variants in genes encoding ARSs are associated with various recessive mitochondrial and multisystem disorders. We describe here a multisystem clinical phenotype based on bi‐allelic mutations in the two genes (FARSA, FARSB) encoding distinct subunits for tetrameric cytosolic phenylalanyl‐tRNA synthetase (FARS1). Interstitial lung disease with cholesterol pneumonitis on histology emerged as an early characteristic feature and significantly determined disease burden. Additional clinical characteristics of the patients included neurological findings, liver dysfunction, and connective tissue, muscular and vascular abnormalities. Structural modeling of newly identified missense mutations in the alpha subunit of FARS1, FARSA, showed exclusive mapping to the enzyme's conserved catalytic domain. Patient‐derived mutant cells displayed compromised aminoacylation activity in two cases, while remaining unaffected in another. Collectively, these findings expand current knowledge about the human ARS disease spectrum and support a loss of canonical and non‐canonical function in FARS1‐associated recessive disease.

22 June 2019 in Bioinformatics
Verified
Journal Article
Open access
TJTim Jeske
Tim Jeske
PHPeter Huypens
Peter Huypens
LSLaura Stirm
Laura Stirm
SHSelina Höckele
Selina Höckele
CWChristine M Wurmser
Christine M Wurmser
MHMaximilian Hastreiter
Maximilian Hastreiter
Summary: Despite their fundamental role in various biological processes, the analysis of small RNA sequencing data remains a challenging task. Major obstacles arise when short RNA sequences map to multiple locations in the genome, align to regions that are not annotated or underwent post-transcriptional changes which hamper accurate mapping. In order to tackle these issues, we present a novel profiling strategy that circumvents the need for read mapping to a reference genome by utilizing the actual read sequences to determine expression intensities. After differential expression analysis of individual sequence counts, significant sequences are annotated against user defined feature databases and clustered by sequence similarity. This strategy enables a more comprehensive and concise representation of small RNA populations without any data loss or data distortion. Availability and implementation: Code and documentation of our R package at http://ibis.helmholtz-muenchen.de/deus/. Supplementary information: Supplementary data are available at Bioinformatics online.